Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
grade B 4.0 -4.31% -0.18
AFMD closed down 4.31 percent on Friday, March 22, 2019, on 1.88 times normal volume.

Earnings due: Mar 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical AFMD trend table...

Date Alert Name Type % Chg
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 21 Jack-in-the-Box Bullish Bullish Swing Setup -4.31%
Mar 21 Calm After Storm Range Contraction -4.31%
Mar 21 Upper Bollinger Band Walk Strength -4.31%
Mar 21 Inside Day Range Contraction -4.31%
Mar 21 Upper Bollinger Band Touch Strength -4.31%
Mar 20 Expansion Breakout Bullish Swing Setup -7.83%
Mar 20 Pocket Pivot Bullish Swing Setup -7.83%
Mar 20 Volume Surge Other -7.83%
Mar 20 Calm After Storm Range Contraction -7.83%

Older signals for AFMD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Medicine Biopharmaceutical Cancer Medical Specialties Solid Tumors Monoclonal Antibodies Lymphoma Glioblastoma Immunotherapies Chronic Lymphocytic Leukemia Hematologic Malignancies Seattle Genetics Head And Neck Cancer Non Hodgkin Lymphoma Tumors Of The Hematopoietic And Lymphoid Tissues Cd30 Hodgkin Lymphoma
Is AFMD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.35
52 Week Low 1.4
Average Volume 560,101
200-Day Moving Average 3.2333
50-Day Moving Average 3.5733
20-Day Moving Average 3.809
10-Day Moving Average 4.028
Average True Range 0.2729
ADX 35.76
+DI 31.1073
-DI 10.3272
Chandelier Exit (Long, 3 ATRs ) 3.8613
Chandelier Exit (Short, 3 ATRs ) 4.0887
Upper Bollinger Band 4.3433
Lower Bollinger Band 3.2747
Percent B (%b) 0.68
BandWidth 28.054608
MACD Line 0.1775
MACD Signal Line 0.1465
MACD Histogram 0.031
Fundamentals Value
Market Cap 175.76 Million
Num Shares 43.9 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -4.02
Price-to-Sales 22.02
Price-to-Book 1.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.30
Resistance 3 (R3) 4.33 4.25 4.25
Resistance 2 (R2) 4.25 4.18 4.24 4.23
Resistance 1 (R1) 4.13 4.13 4.09 4.10 4.22
Pivot Point 4.05 4.05 4.04 4.04 4.05
Support 1 (S1) 3.93 3.98 3.89 3.90 3.78
Support 2 (S2) 3.85 3.93 3.84 3.77
Support 3 (S3) 3.73 3.85 3.75
Support 4 (S4) 3.70